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Altered β1−3-adrenoceptor influence
on α2-adrenoceptor-mediated
control of catecholamine release and
vascular tension in hypertensive rats
Torill Berg*
Division of Physiology, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo,
Norway
α2- and β-adrenoceptors (AR) reciprocally control catecholamine release and vascular
tension. Disorders in these functions are present in spontaneously hypertensive
rats (SHR). The present study tested if α2AR dysfunctions resulted from altered
α2AR/βAR interaction. Blood pressure (BP) was recorded through a femoral artery
catheter and cardiac output by an ascending aorta flow probe. Total peripheral
vascular resistance (TPR) was calculated. Norepinephrine release was stimulated by
a 15-min tyramine-infusion, which allows presynaptic release-control to be reflected
as differences in overflow to plasma. Surgical stress activated some secretion
of epinephrine. L-659,066 (α2AR-antagonist) enhanced norepinephrine overflow in
normotensive controls (WKY) but not SHR. Nadolol (β1+2) and ICI-118551 (β2), but
not atenolol (β1) or SR59230A [β(3)/1L] prevented this increase. All βAR antagonists
allowed L-659,066 to augment tyramine-induced norepinephrine overflow in SHR and
epinephrine secretion in both strains. Inhibition of cAMP-degradation with milrinone
and β3AR agonist (BRL37344) enhanced the effect of L-659,066 on release of both
catecholamines in SHR and epinephrine in WKY. β1/2AR antagonists and BRL37344
opposed the L-659,066-dependent elimination of the TPR-response to tyramine in
WKY. α2AR/βAR antagonists had little influence on the TPR-response in SHR. Milrinone
potentiated the L-659,066-dependent reduction of the TPR-response to tyramine.
Conclusions: β2AR activity was a required substrate for α2AR auto inhibition of
norepinephrine release in WKY. β1+2AR opposed α2AR inhibition of norepinephrine
release in SHR and epinephrine secretion in both strains. βAR-α2AR reciprocal control
of vascular tension was absent in SHR. Selective agonist provoked β3AR-Gi signaling
and influenced the tyramine-induced TPR-response in WKY and catecholamine release
in SHR.
Keywords: α2-adrenoceptors, β-adrenoceptors, hypertension, total peripheral vascular resistance, sympathetic
nervous system, catecholamine release, spontaneously hypertensive rats
Introduction
α2- and β-adrenoceptors (AR) comprise the α2A,B,and C and the β1,2,and 3 subtypes. By coupling to
inhibitory (Gi) and stimulatory (Gs) G-proteins, respectively, α2A,B,C- and β1+2AR have opposite
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effect on adenylyl cyclase, and therefore have reciprocal actions
on various functions involved in the control of blood pressure
(BP), including the release of catecholamines and vascular ten-
sion. The β3AR has been shown to couple to Gi and induce a neg-
ative inotropic effect in the heart (Gauthier et al., 1998). Trans-
mitter release from peripheral sympathetic nerves is inhibited
by presynaptic α2AR, primarily the α2A-subtype (Trendelenburg
et al., 2003; Berg and Jensen, 2013), and stimulated by presy-
naptic β2AR (Stjarne and Brundin, 1976; Westfall et al., 1979).
Also the β1AR has recently been demonstrated to enhance nore-
pinephrine release, providing a plausible rational for the antihy-
pertensive action of β1AR antagonists, the most frequently used
β-blockers in the treatment of hypertension (Berg, 2014a). α2AR
auto-receptors in addition inhibited adrenal epinephrine secre-
tion in in vivo experiments (Brede et al., 2003; Berg et al., 2012),
whereas β1- or β2AR antagonists had no effect (Berg, 2014a).
α2AR-mediated auto inhibition of neuronal and adrenal cate-
cholamine release has been shown to be dysfunctional in the
spontaneously hypertensive rat (SHR) (Berg and Jensen, 2013).
This dysfunction may contribute to the hyper adrenergic and
hypertensive state in this model of human hypertensive disease,
in agreement with the high plasma norepinephrine concentration
and hypertension observed in α2AAR-gene-deleted mice (Makar-
itsis et al., 1999). The failing α2AR auto inhibition in SHR may
result from an altered interaction between different presynaptic
receptors, as indicated by the restored α2AR function in SHR
after α2CAR stimulation or angiotensin AT1 receptor inhibition
(Berg, 2013) (Figure 1). The β3AR has been shown to be less
sensitive to catecholamine-induced desensitization than the β1-
and β2AR (Mallem et al., 2004; Rouget et al., 2004), and a β3AR
up-regulated and β1AR down-regulated relaxation was demon-
strated in SHR thoracic aortic rings (Mallem et al., 2004). It may
therefore be hypothesized that alterations in βAR signaling may
alter α2AR auto inhibition of catecholamine release in SHR.
α2BAR (Philipp et al., 2002) and βAR are also present in
vascular smooth muscle cells (VSMC), where they modulate
the α1AR-mediated vasoconstrictory response to norepinephrine
(Figure 2). VSMC tension is in addition influenced by endothe-
lial α2AAR and β2AR, which both stimulate nitric oxide (NO)
synthesis (Shafaroudi et al., 2005; Queen et al., 2006). Also
vasodilatory and vasoconstrictory α2AR-mediated control of
total peripheral vascular resistance (TPR) appeared dysfunctional
in SHR (Berg and Jensen, 2011, 2013).
Presynaptic receptors modulate norepinephrine release from
the nerve terminal vesicles. This control is not reflected by dif-
ferences in norepinephrine overflow to plasma, due to that the
response is terminated by re-uptake through the norepinephrine
re-uptake transporter (NET). Presynaptic control of release is
therefore not easily studied in vivo. However, tyramine stimulates
norepinephrine release by reversing the transport through NET
(Figure 1), and consequently prevents re-uptake through NET.
Presynaptic modulation of concomitant vesicular release can
therefore be demonstrated as differences in overflow to plasma
(Berg et al., 2012; Berg and Jensen, 2013). The presynaptic recep-
tors will be stimulated by the released norepinephrine and/or
by other agonists present in the vicinity. Secreted epinephrine
is not subjected to re-uptake through NET, and was therefore
not influenced by tyramine, but was stimulated to some extent
by the stress induced by the experiment itself (Berg et al.,
2012). Thus, the inhibitory effect of presynaptic α2AR on cat-
echolamine release could be demonstrated by the ability of
the non-selective, peripherally restricted, α2AR antagonist L-
659,066 to increase tyramine-induced norepinephrine overflow
and epinephrine secretion (Berg and Jensen, 2013). The stimulat-
ing effect of presynaptic βARwas demonstrated by pre-treatment
with β1or2AR antagonists (Berg, 2014a). Inhibition of release
could be stimulated in SHR by the β3AR agonist BRL37344, com-
patible with stimulation of β3AR-Gi activation (Berg, 2014b). The
reduced release observed after the β3AR antagonist SR59230A
was likely to result from its inhibitory effect on the Gs-coupled
low-affinity state β1AR (β1LAR) (Berg, 2014b). The use of tyra-
mine also allowed a concomitant examination of the role of post-
synaptic α2AR and βAR in the cardiovascular response to the
released norepinephrine (Figure 2).
The purpose of the present investigation was therefore to
gain a better understanding of the reason underlying the fail-
ing α2AR auto-inhibition of catecholamine release in SHR, i.e., to
test if there was a difference in the interaction between the α2AR
and the three βAR subtypes in this strain compared to that in
their normotensive controls (WKY). A second goal was to test
if a difference in β1−3AR activity was responsible for the failing
α2AR influence on the TPR-response to the tyramine-stimulated
norepinephrine release in SHR.
Materials and Methods
Experimental Procedure
All experiments were approved by The Norwegian Animal
Research Authority (NARA) and conducted in accordance with
the Directive 2010/63/EU of the European Parliament. Male, 12–
14 weeks old SHR (Okamoto, SHR/NHsd strain, 273 ± 2 g body
weight, n = 109) and their normotensive control, i.e., WKY
(Wistar Kyoto, 279± 9 g body weight, n = 124) on conventional
rat chow diet (0.7% NaCl) were anesthetized with sodium pen-
tobarbital (65–70mg/kg, IP) and tracheotomized. A heparinized
catheter was inserted into the femoral artery to record systolic
(SBP) and diastolic (DBP) BP. The rats were subsequently con-
nected to a positive-pressure respirator and ventilated with air
throughout the experiment. Cardiac output (CO, i.e., minus car-
diac flow) and heart rate (HR) were recorded by a flow probe
on the ascending aorta, connected to a T206 Ultrasonic Transit-
Time Flowmeter (Transonic Systems Inc., Ithaca, NY, USA).
After surgery was completed, the arterial catheter was flushed
with 0.15ml heparinized (1000 U/ml) phosphate-buffered saline
(PBS; 0.01M Na-phosphate, pH 7.4, 0.14M NaCl). Mean arterial
BP [MBP = (SBP-DBP/3) + DBP] and TPR (=MBP/CO) were
calculated. Body temperature was maintained at 37 − 38◦C by
external heating, guided by of a thermo sensor inserted inguinally
into the abdominal cavity. Drugs were dissolved in PBS and
administered as bolus injections (0.6–1ml/kg) through a catheter
in the femoral vein, unless otherwise indicated.
Experimental Design
After a control period of about 10min, control rats were
pre-treated with vehicle (PBS), and subsequently infused with
tyramine for 15min (1.26µmol/kg/min) (Berg, 2005; Berg and
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FIGURE 1 | Control of norepinephrine release from peripheral
sympathetic nerve endings. Tyramine stimulates norepinephrine
release by reverse transport through NET. Consequently, re-uptake
through NET is prevented, and presynaptic modulation of vesicular
release is reflected as differences in overflow to plasma (Berg et al.,
2012; Berg and Jensen, 2013). The release of norepinephrine from
secretory granules is activated by adenylyl cyclase, which is stimulated
by β1,1L,2AR-Gs and inhibited by α2AR-Gi. In WKY, α2AR auto
inhibition required β2AR activity, but was independent of β1AR
signaling. In SHR, blocking β1,1L,2AR activity allowed α2AR inhibition
of release. The β3AR-selective agonist BRL37344 reduced
norepinephrine overflow in SHR but not WKY (dotted arrow). The
β3AR antagonist SR59230A reduced overflow apparently due to its
abililty to inhibit β1LAR and not the β3AR. The action of antagonists
and agonist are indicated. NE, norepinephrine; Pointed arrows, postive
effects; Blunted arrows, inhibitory actions.
Jensen, 2013). In the experimental groups, the rats were pre-
treated with drugs to modify presynaptic and postsynaptic α2AR
or βAR signaling, separately or combined.
Inhibition of βAR-Signaling
Inhibition of βAR-signaling was achieved by βAR-antagonists,
the peripherally restricted, i.e., which does not cross the blood-
brain barrier, nadolol (β1+2, 8.5µmol/kg), or atenolol (β1,
5.6µmol/kg), the not-restricted ICI-118551 (β2, 1µmol/kg ini-
tial dose, then 0.3µmol/kg/min throughout the experiment)
or the β3AR antagonist SR59230A (13.8µmol/kg) (Berg et al.,
2010). SR59230A also inhibited the putative β4AR (Malinowska
and Schlicker, 1997), later identified as β1LAR (Kaumann et al.,
2001).
Amplification of βAR-Signaling
Amplification of βAR-signaling was achieved by pre-treatment
with the phosphodiesterase 3 (PDE3) inhibitor milrinone
(1.4µmol) (Berg et al., 2009) which will prevent degra-
dation of cyclic AMP (cAMP) (Figure 2). The β3AR was
stimulated by the agonist BRL37344 ((±)-(R∗,R∗)-[4-[2-[[2-(3-
Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]-acetic
acid sodium hydrate) infused at a rate of 1 nmol/kg/min
throughout the experiment (Malinowska and Schlicker, 1997;
Berg, 2014b).
Inhibition of α2AR-Signaling
Inhibition of α2AR-signaling was achieved by pre-treatment with
the none-selective, peripherally restricted α2AR antagonist L-
659,066 (Clineschmidt et al., 1988) (4.4µmol/kg) (Berg et al.,
2012; Berg and Jensen, 2013).
Inhibition of Gi Signaling
Since Gi represents a main signaling pathway for all α2AR,
Gi-signaling was abolished by the Gi-inhibitor Bordetella pertus-
sis toxin (PTX, 15µg/kg, i.p., −48 h) (Anand-Srivastava et al.,
1987). The latter rats were pre-treated with PBS during the
experiment.
The Interaction between α2AR and βAR Signaling
The interaction between α2AR and βAR signaling was stud-
ied by combining βAR antagonists/agonist/milrinone with the
α2AR antagonist L-659,066 as indicated in Table 1. Ten min was
allowed between drugs, except for SR59230A which was followed
by L-659,066 or tyramine after 5min.
Measurement of Plasma Catecholamines
1.5ml blood was collected from the femoral artery into
tubes containing 45µl 0.2M glutathione and 0.2M ethy-
lene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid
(EGTA) (4◦C). Plasma was stored at −80◦C until catecholamine
concentrations were determined using 400µl plasma and the
5000 Reagent kit for HPLC analysis of catecholamines in plasma
from chromsystems GmbH, Munich, Germany, as described
by the manufacturer. The samples were run on a Shimadzu
monoamines analyzer system, using an isocratic flow rate of
0.8ml/min, and an electrochemical detector (Decade II) and a
SenCell electrochemical flow cell (Antec Leyden, Zoeterwoude,
The Netherlands).
Drugs
L-659,066 was a kind gift from Merck, Sharp and Dohme
Labs, Rahway, NJ. ICI-118551 was obtained from ICI-Pharma,
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FIGURE 2 | AR-mediated control of tension in VSMC. Inhibition of KV
induces depolarization which will activate Ca2+ influx through Cav and thus
precipitates vasoconstriction due to a rise in [Ca2+]i. KV is stimulated by
cAMP-PKA signaling, and in pathophysiologic conditions such as that in SHR
may be inhibited by PLC. The BRL37344-induced β3AR-Gi signaling and
increased TPR was only observed in WKY during tyramine-induced
norepinephrine release. Cav, voltage sensitive Ca2+ channels; KV, voltage
sensitive K+ channels; 4AP, the KV inhibitor 4-aminopyridine; PKA, protein
kinase A; Arrow, positive action; Blunted arrow, negative action.
Cheshire, UK; SR59230A from Santa Cruz Biotechnology, Hei-
delberg, Germany; and pentobarbital from The Norwegian
National Hospital, Oslo, Norway. The remaining drugs were
from Sigma Chemical Co., St. Louis, MO, USA.
Statistical Analyses
Results are presented as mean values ± s.e.m. Effect of pre-
treatment, differences in the cardiovascular baselines, (data aver-
aged every min), and the plasma catecholamine concentrations
were evaluated by overall tests (One-Way ANOVA), followed
by two-tailed two-sample Student’s t-tests. The cardiovascular
response-curves to tyramine (data averaged every min) were ana-
lyzed using Repeated Measures Analyses of Variance and Covari-
ance, first as over-all tests, subsequently for each group separately
or between two groups. Significant responses and groups differ-
ences were subsequently located at specific times using two-tailed
one- and two-sample Student’s t-tests, respectively. For non-
parametric data, two-sample Student’s t-tests were substituted by
Kruskal–Wallis tests. At each step, testing proceeded only when
the presence of significant differences and/or interactions was
indicated. For the cardiovascular data, the P-value was for all
tests and each step adjusted according to Bonferroni, whereas
P ≤ 0.05 was considered significant for the catecholamine
data.
In those cases, where comparisons were made with rats
included in previous publications (Table 1), these experiments
were performed, in part or in full, intermittently with the
present groups. When this was not the case, some of the pre-
vious experiments were substituted with new to ensure that
all experiments overlapped in time. Control rats were included
randomly throughout the study.
Results
The Influence of β1−3AR Signaling on
α2AR-mediated Inhibition of Tyramine-induced
Norepinephrine Overflow to Plasma
The Effect of Modulating βAR Signaling
As previously described (Berg and Jensen, 2013; Berg, 2014a),
all βAR antagonists, including SR59230A, reduced the tyramine-
induced overflow of norepinephrine to plasma in both strains
(Figure 3). Since the effect of SR59230A was likely to involve
inhibition of βILAR rather than β3AR (Berg, 2014b), this result
demonstrated that the overflow was enhanced by β1+1L+2AR
activation. However, the β3AR agonist BRL37344 precipitated a
minor reduction in overflow in SHR but not WKY (Figure 4),
compatible with a Gi-mediated inhibition of release in SHR
(Berg, 2014b).
The Effect of inhibiting α2AR-Gi Signaling
The Gi inhibitor PTX had no significant effect on the tyramine-
induced norepinephrine overflow in either strain (Figure 4). As
before (Berg and Jensen, 2013), the α2AR antagonist L-659,066
increased norepinephrine overflow in WKY, but the rise was not
statistically significant in SHR (Figures 3, 4).
The Interaction between α2AR and βAR Signaling
L-659,066 eliminated the reduction in the tyramine-induced
overflow induced by the β1AR antagonist atenolol in WKY
(P = NS compared to the controls or L-659,066 alone,
P = 0.004 compared to atenolol alone) (Figure 3). L-659,066
also totally reversed the reduction following pre-treatment with
the β(3)+ILAR antagonist SR59230A (P = 0.005 compared to
SR59230A alone, P=NS compared to the controls and L-659,066
alone) (Figure 3). However, L-659,066 counter-acted only in
part the reduction following the β1+2AR antagonist nadolol
(P ≤ 0.004 compared to the WKY controls and L-659,066 alone,
P = 0.049 compared to nadolol alone), and did not at all
counter-act the reduction induced by the β2-selective antagonist
ICI-118551 (P = 0.05 and 0.005 compared to the controls and
L-659,066 alone, respectively, P = NS compared to ICI-118551
alone) (Figure 3). These results demonstrated that α2AR antag-
onist increased tyramine-stimulated norepinephrine release in
WKY also in the presence of β1AR and β(3)+1LAR antagonist, but
not when the β2AR subtype was blocked.
The plasma norepinephrine concentration in L-659,066 +
milrinone-treated WKY was higher than that in the controls
(P = 0.05) but not different from that after L-659,066 alone
(Figure 4). This result showed that enhanced cAMP signaling,
i.e., down-stream of adenylyl cyclase (Figure 2), did not influ-
ence the response to L-659,066 in this strain. BRL37344 did not
alter the effect of L-659,066 on tyramine-induced norepinephrine
release (Figure 4), demonstrating that β3AR-Gi signaling did not
contribute to the response in WKY.
In SHR, L-659,066 eliminated the reduction in tyramine-
induced norepinephrine overflow induced by all four βAR antag-
onists (P ≤ 0.003 compared to βAR-antagonist alone), and
was higher than that in the controls in all groups (P ≤ 0.018),
except in the ICI-118551 + L-659,066-treated group (P = NS)
(Figure 3). These results demonstrated that α2AR-mediated
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TABLE 1 | Cardiovascular baselines after pre-treatment, i.e., prior to tyramine and, in parenthesis, the response to pre-treatment.
Pre-treatment WKY SHR
MBP HR CO TPR MBP HR CO TPR
mm Hg beats/min ml/min mm Hg/ml/min mm Hg beats/min ml/min mm Hg/ml/min
PBS (control)b 66± 3 341± 8 32±2 2.1±0.1 92± 5* 391±5* 19± 1* 4.6± 0.2*
(−3± 2) (−6± 4) (2±0) (−0.3±0.1) (−5± 5) (−16±5) (0± 1) (−0.3± 0.2)
INHIBITION OF βAR SIGNALING
Nadolol
(β1+2ANT)
b
65± 2 338± 5 31±2 2.1±0.1 64± 5† 345±10† 13± 2† 4.6± 0.5
(−3± 1) (−21± 6) (1±1) (−0.2±0.0) (−25± 2)† (−80±7)† (−1± 1) (−2.0± 0.8)†
Atenolol
(β1ANT)
b
61± 2 338± 9 28±2 2.4±0.1 63± 3† 338±9 13± 1† 5.1± 0.4
(−12± 1) (−32± 7)† (1±1) (−0.5±0.1) (−32± 5)† (−69±10)† (−4± 1) (−0.4± 0.5)
ICI-118551
(β2ANT)
b
50± 4 311± 12 28±4 1.8±0.1 70± 4 358±7† 18± 1 4.3± 0.2
(−6± 2) (−31± 4)† (2±1) (−0.4±0.1) (−23± 4) (−59±8)† (1± 1) (−1.2± 0.2)
SR59230A
(β3 + β1L ANT)
b
84± 4† 390± 8† 27±2 3.3±0.3† 90± 8 424±13 18± 2 5.1± 0.4
(10± 3)† (30± 7)† (4±1) (−0.2±0.2) (−6± 5) (−21±5) (0± 1) (−0.5± 0.3)
STIMULATION OF THE βAR SIGNALING PATHWAY
Milrinone (PDE3
INH)
40± 2† 343± 7 30±2 1.4±0.1† 52± 3† 413±14 18± 1 2.9± 0.2†
(−35± 1)† (2± 8) (−2±1) (−1.0±0.1)† (−59± 7)† (−1±9) (−4± 1) (−2.4± 0.5)†
BRL44408
(β3AGON)
b
51± 2† 312± 9 44±4 1.2±0.1† 109± 7 409±15 23± 1† 4.8± 0.3
(3± 3) (−8± 9) (9±2)† (−0.6±0.1)† (−9± 7) (0±9) (4± 1)† (−0.4± 0.3)
INHIBITION OF α2AR-Gi SIGNALING
PBS after PTX
(Gi INH)
a
52± 3 338± 9 39±4 1.3±0.2† 65± 5 389±12 22± 3 3.3± 0.5
(−2± 2) (−21± 4) (3±1) (−0.1±0.1) (−8± 6) (−24±11) (−1± 2) (−0.5± 0.2)
L-659,066
(α2ANT)
b
59± 7 345± 11 35±2 1.7±0.1 69± 6† 398±12 17± 1 4.3± 0.4
(−17± 2)† (−10± 5) (2±0) (−0.6±0.0)† (−21± 4)† (−16±10) (−1± 0) (−1.1± 0.2)
INTERACTION BETWEEN βAR AND α2AR SIGNALING
Nadolol +
L-659,066
47± 6‡ 323± 8 23±3 2.0±0.1 61± 4† 356±8† 15± 2 4.4± 0.4
(−6± 2)⊣ (−30± 10) (3±2) (−0.7±0.2) (−18± 7) (−69±9)†⊣ (−1± 1) (−0.8± 0.6)
Atenolol +
L-659,066
56± 5 340± 10 27±4 2.2±0.2 67± 5 363±8 14± 1 4.7± 0.3
(−18± 5)† (−52± 18)† (5±2) (−1.1±0.3)† (−35± 4)†⊣ (−90±7)†⊣ (0± 1) (−2.3± 0.2)†‡⊣
ICI-118551 +
L-659,066
49± 4 336± 7 26±1 1.9±0.2 77± 7 356±4† 19± 1 4.0± 0.1†
(−26± 3)†‡ (−39± 7)†⊣ (1±1) (−1.2±0.1)†⊣ (−16± 9) (−68±1)†⊣ (0± 1) (−1.1± 0.2)
SR59230A +
L-659,066
55± 6‡ 364± 25 28±3 2.0±0.2‡ 88± 9 408±11 19± 2 4.7± 0.4
(−3± 4)‡ (23± 9)⊣ (2±3) (−0.3±0.2) (−3± 9) (2±9) (−1± 1) (0.2± 0.4)
Milrinone +
L-659,066
37± 1† 366± 12 28±2 1.3±0.1†⊣ 39± 2†‡⊣ 431±9† 19± 1 2.2± 0.2†⊣
(−42± 6)† (−5± 5) (1±2) (−1.5±0.2)† (−62± 6)†⊣ (0±15) (−2± 1) (−3.0± 0.4)†⊣
BRL44408 +
L-659,066
41± 4† 379± 11‡ 45±8 1.0±0.1† 77± 8‡ 407±5 25± 1†⊣ 3.1± 0.2†‡
(−28± 6)†⊣ (20± 9) (10±7) (−1.0±0.1)†‡⊣ (−33± 9)†‡ (2±6) (4± 2) (−2.4± 0.5)†‡⊣
aSince PTX was given 4 h prior to the experiment, its effect was reflected as differences in the baselines themselves. Comparisons were made between WKY and SHR controls (* after
SHR-values) and between the PBS-controls and the experimental groups, using the response to PBS to evaluate the effect of pre-treatment (†). Comparisons were also made between
groups pre-treated with βAR-antagonist + α2AR-antagonist and corresponding groups pre-treated with βAR-antagonist alone (
‡) or α2AR-antagonist alone (
⊣).
bThe rats in these groups were in part or in full the same as in (Berg and Jensen, 2013; Berg, 2014a,b). Six to ten rats were included in each group, except for the WKY and SHR
controls and the SHR ICI-118551 and L-659,066 groups which comprised 17, 18, 13, and 13 rats, respectively. *, P ≤ 0.05; †, P ≤ 0.0036; ‡, ⊣, P ≤ 0.0083.
auto inhibition of norepinephrine release was opposed by both
β1+1LAR and β2AR activity in SHR, with the β1AR having the
greatest impact. Norepinephrine overflow was also increased
after pre-treatment with L-659,066 + milrinone (P ≤ 0.001
compared to the control, milrinone- or L-659,066-only groups),
showing that α2AR auto inhibition was enhanced by inhibi-
tion of cAMP degradation. In addition, the effect of L-659,066
on overflow was higher when combined with the β3AR ago-
nist BRL37344 (P ≤ 0.006 compared to the controls and after
BRL37344 or L-659,066 alone) (Figure 4).
The Effect of PTX, β1−3AR Antagonists, Milrinone,
and β3AR Agonist on α2AR-mediated Inhibition of
Epinephrine Secretion
The Effect of Modulating βAR Signaling
The βAR antagonists (Figure 3), milrinone and β3AR agonist
(Figure 4) had by themselves no effect on the concentration of
epinephrine in plasma collected at the end of the experiment
in either strain, except for a minor reduction after SR59230A
(Figure 3) and an increase after milrinone (Figure 4) in SHR
(P ≤ 0.04).
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FIGURE 3 | The effect of βAR antagonist, alone or combined with the
α2AR antagonist L-659,066, on the plasma concentration of
norepinephrine and epinephrine. Blood was sampled immediately after the
15-min tyramine-observation period, but without discontinuing the
tyramine-infusion. Significant differences between the control groups
pre-treated with PBS and the experimental groups (* above columns), and
between the corresponding groups pre-treated with βAR antagonist and βAR
antagonist + L-659,066 (* in bar) were located as indicated. The βAR
antagonist (ant) used is indicated below columns; β1+2AR ant = nadolol,
β1AR ant = atenolol, β2AR ant = ICI-118551, and β(3)+1LAR ant = SR59230A
which preferably acts as an antagonist to the Gs-coupled low-affinity state
β1AR (Berg, 2014b). *P ≤ 0.05.
The Effect of Inhibiting α2AR-Gi Signaling (Figure 4)
PTX clearly increased the secretion of epinephrine in both strains
(P ≤ 0.032), demonstrating a tonic Gi-mediated inhibition of
epinephrine release. Some increase in the plasma epinephrine
concentration was observed in L-659,066-pre-treated WKY (P =
0.048) and, in this collection of animals, also in the L-659,066-
pre-treated SHR (P = 0.004). This observation demonstrated
that part of the tonic inhibition of release was due to α2AR
activity.
The Interaction between α2AR and βAR Signaling
However, when L-659,066 was combined with βAR-antagonist
(Figure 3), the plasma epinephrine concentration was for all
groups in both strains higher than that in the corresponding con-
trols or after each drug alone (P ≤ 0.05). These results demon-
strated that βAR signaling interfered with α2AR auto inhibition
of epinephrine secretion. The only exceptions were the WKY
SR59230A+ L-659,066-pre-treated group where the plasma con-
centration was not different from that in the controls or after
each antagonist alone, and the SHR ICI-118551 + L-659,066
group, which was not different from that after L-659066 alone
(Figure 3). A potentiated effect of L-659,066 was also seen when
L-659,066 was combined with milrinone or the β3AR-agonist
BRL37344 (Figure 4).
FIGURE 4 | The effect of Gi- α2AR inhibition, increased cAMP or β3AR
signaling on the plasma concentration of norepinephrine and
epinephrine. Total Gi inhibition was achieved by PTX and α2AR inhibition by
L-659,066. Increased cAMP signaling was done by preventing its degradation
using the PDE3 inhibitor milrinone. BRL37344 was used to stimulate β3AR
signaling. Significant differences between the control groups pre-treated with
PBS and the experimental groups (* above columns), and between
corresponding groups pre-treated with milrinone or β3AR agonist without and
with additional pre-treatment with L-659,066 (* in bar) were located as
indicated. *P ≤ 0.05.
The Role of β1−3AR and α2AR in the Control of
Cardiovascular Baselines (Table 1)
As previously documented (Berg et al., 2010; Berg, 2014a),
nadolol, atenolol, and ICI-118551 reducedHR inWKY, andMBP,
HR and TPR baselines in SHR, although the difference was not
statistically significant for all. SR59230A increased MBP and HR
in WKY but had no effect in SHR (Berg, 2014b). Milrinone alone
had no significant effect on baseline HR or CO, but reducedMBP
and TPR in both strains (P ≤ 0.003 compared to the controls).
BRL37344 itself reduced TPR baseline in WKY and increased
CO baseline in both strains (Berg, 2014b). Baselines in rats pre-
treated with the Gi inhibitor PTX were not significantly different
from that in the controls (P ≥ 0.0036), except for a reduced TPR
in WKY. L-659,066 reduced baseline MBP in both strains and
TPR significantly in WKY only.
After nadolol/atenolol/ICI-118551 + L-659,066, changes in
the cardiovascular baselines in WKY were largely the same as the
combined effect of that observed after the βAR and α2AR antag-
onists alone, except for a greater fall in TPR after ICI-118551
+ L-659,066 (P ≤ 0.005 compared to that after each antag-
onist alone). In SHR, TPR baseline was reduced after atenolol
+ L-659,066 (P ≤ 0.008 compared to that after each antago-
nist alone), whereas the reduction following nadolol alone was
not observed after nadolol + L-659,066. The TPR-response to
milrinone + L-659,066 was not different from that after mil-
rinone alone in either strain, but was greater than that after
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L-659,066 alone in SHR (P ≤ 0.005). After BRL37344 + L-
659,066, the changes seen after BRL37344 or L-659,066 alone
remained, but inWKY there was a further reduction in TPR (P ≤
0.008 compared to BRL37344 or L-659,066 alone). L-659,066 had
no effect on HR or CO baselines in either strain, and did not
alter the HR-response to βAR antagonist, milrinone or β3AR
agonist.
The Influence of β1−3AR and α2AR on the
TPR-response to Tyramine-stimulated
Norepinephrine Release
In agreement with previous studies (Berg et al., 2010; Berg and
Jensen, 2013), the tyramine-induced release of norepinephrine
activated a transient rise in TPR (Figures 5, 6) and a sustained
increase in HR (Figures 7, 8), MBP and CO (not shown) in
both strains. Pre-treatment with PTX or L-659,066 eliminated
the TPR-response to tyramine in WKY (P ≤ 0.001 compared to
WKY controls,P = NS for single curve evaluation), and in SHR
reduced the TPR-peak response (P ≤ 0.008), but had no effect
on the later response (Figure 5). Milrinone reduced the TPR-
peak response in both strains (Figure 5). After pre-treatment
with milrinone+ L-659,066, the tyramine-induced vasoconstric-
tion was reversed to a vasodilatory response in WKY (P ≤ 0.025
compared to the control and milrinone-only groups at 3 and
15min), and eliminated in SHR (P = NS, single curve evalua-
tion) (Figure 5). When the β3AR agonist BRL37344 was given
prior to L-659,066, the TPR-response to tyramine was higher than
that after L-659,066 alone in WKY (P = 0.024 at 15min) but not
different in SHR (Figure 5).
The L-659,066-dependent elimination of the TPR-response to
tyramine in WKY was in part reversed by prior administration
of nadolol, atenolol or ICI-118551, with a non-additive effect of
β1- and β2AR blockade (Figure 6). Significant differences were
not detected between the L-659,066 and the βAR antagonist
+ L-659,066 pre-treated groups in SHR (Figure 6). When the
β3+1LAR antagonist SR59230A was combined with L-659,066,
the TPR-response to tyramine was not altered in WKY, whereas
the vasoconstriction developed more slowly than after L-659,066
alone in SHR (Figure 6).
The Influence of β1−3AR and α2AR on the
Tyramine-induced Tachycardia
The tyramine-induced tachycardia was not influenced in either
strain by inhibition of α2AR-Gi-signaling by L-659,066 or PTX,
or by inhibition of cAMP-degradation by milrinone or stimu-
lation of β3AR with BRL37344, either alone or combined with
L-659,066 (Figure 7). The only exception was milrinone + L-
659,066 which halved the HR-response in SHR (P ≤ 0.028)
(Figure 7). As after nadolol alone (Berg et al., 2010), nadolol +
L-659,066 eliminated the tachycardia in both strains (Figure 8).
1HR was clearly reduced after atenolol + L-659,066 and to
some extent also after SR59230A + L-659,066 in both strains
FIGURE 5 | βAR and α2AR influence on the TPR-response
to tyramine-induced norepinephrine release in WKY and
SHR. The rats were pre-treated as indicated by symbol
legends. Significant responses (* within symbol) and differences
between groups at peak-response (brackets left of curves) and
at 15min (brackets right of curves) were located as
indicated. Comparisons were made between the control and
the experimental groups, and between corresponding groups
pre-treated with L-659,066 and milrinone + L-659,066.
Baselines prior to tyramine are shown in Table 1. *P ≤ 0.025
after curve evaluation (please see Materials and Methods for
details).
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FIGURE 6 | The effect of βAR antagonists on the α2AR-influence on
the TPR-response to tyramine-induced norepinephrine release in
WKY and SHR. The rats were pre-treated with the peripherally restricted
α2AR antagonist L-659,066, alone or combined with βAR antagonist, as
indicated by symbol legends. Significant responses (* within symbol) and
differences between groups at peak-response (brackets left of curves)
and at 15min (brackets right of curves) were located as indicated.
Comparisons were made between the control and the experimental
groups, and between corresponding L-659,066 and βAR antagonist +
L-659,066 groups. Baselines prior to tyramine are shown in Table 1.
*P ≤ 0.025 after curve evaluation (please see Materials and Methods for
details).
(Figure 8), not different from that previously observed after
atenolol and SR59230A alone (Berg et al., 2010). Different from
that previously documented for ICI-118551 alone, i.e., no effect
on the HR-response to tyramine in WKY and a slightly reduced
response in SHR (Berg et al., 2010), ICI-118551 + L-659,066
reduced the tachycardia in WKY, but slightly increased the
response in SHR (Figure 8). The effect of these drugs on the HR-
response to tyramine was not paralleled by similar changes in the
plasma catecholamine concentrations.
Discussion
The main results in the present study were: (1) The α2AR antago-
nist L-659,066 required the presence of β2AR activity to enhance
tyramine-induced norepinephrine overflow in WKY but was
independent of β1AR signaling. (2) α2AR-mediated auto inhibi-
tion of norepinephrine release in SHR and epinephrine secretion
in both strains was opposed primarily by β1+1LAR but also by
β2AR activity. (3) α2AR and β1+2AR reciprocally modulated the
TPR-response to the released norepinephrine in WKY but not
in SHR. (4) In the presence of L-659,066, β3AR agonist stimu-
lated vasoconstriction in WKY and α2AR auto inhibition in SHR
during tyramine-induced norepinephrine release.
The reduction in tyramine-induced norepinephrine overflow
to plasma after the β1AR antagonist atenolol was eliminated by
additional pre-treatment with L-659,066 in WKY. The same was
observed with the β3+1LAR antagonist SR59230A, most likely
due to its ability to inhibit β1LAR (Berg, 2014b) (Figure 1).
L-659,066 therefore increased release independent of β1+1LAR
activity. However, the reduction induced by β2AR blocking
antagonist, i.e., nadolol or ICI-118551, was somewhat or not
at all reversed by L-659,066, respectively. It therefore appeared
that β2AR-induced stimulation of release was a required sub-
strate for α2AR auto inhibition in WKY. Since L-659,066 alone
increased the tyramine-induced norepinephrine overflow in
WKY, the β2AR were evidently active in stimulating release.
However, amplifying the response to β2AR-Gs signaling by
inhibiting PDE3-induced cAMP degradation with milrinone, did
not enhance the effect of L-659,066 inWKY. Also the Gi inhibitor
PTX did not alter norepinephrine overflow. These results may
suggest that α2AR-Gi inhibition of norepinephrine release was
activated in balance with β2AR-Gs stimulation of release. This
balancemay possibly result from a cAMP-PKA-dependent switch
in β2AR-signaling from Gs to Gi (Daaka et al., 1997) when cAMP
reached a certain level.
In SHR, where L-659,066 did not increase tyramine-induced
norepinephrine overflow, additional pre-treatment with β1-
as well as β2AR blockade allowed L-659,066 to increase the
plasma norepinephrine concentration. Also SR59230A + L-
659,066 increased norepinephrine overflow, most likely due
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FIGURE 7 | βAR and α2AR influence on the HR-response to
tyramine-induced norepinephrine release in WKY and SHR.
The rats were pre-treated as indicated by symbol legends.
Significant differences between groups after 15min (brackets right
of curves) were located as indicated. Comparisons were made
between the control and the experimental groups, and between
corresponding groups pre-treated with L-659,066 and milrinone +
L-659,066. Baselines prior to tyramine are shown in Table 1.
*P ≤ 0.05 after curve evaluation (please see Materials and Methods
for details).
to inhibition of the release-stimulating β1LAR. Thus, both
β1 and 1LAR and β2AR counter-acted α2AR-mediated inhibition
of norepinephrine release in SHR, different from that in WKY.
It therefore appeared that excessive β1+2AR activity interfered
with the inhibitory effect of α2AR-Gi on adenylyl cyclase in this
strain.
Surprisingly, L-659,066 combined with the PDE3 inhibitor
milrinone doubled norepinephrine release in SHR, even though
milrinone alone had no effect. Thus, accumulation of cAMP after
preventing its degradation greatly enhanced release only when
the inhibitory action of α2AR-Gi on adenylyl cyclase was pre-
vented (Figure 1). The fact that this was observed in SHR only
was compatible with the augmented βAR hampering of α2AR
auto inhibition in this strain.
Augmented norepinephrine overflow was also observed in
SHR when L-659,066 was combined with BRL37344. Since
BRL37344 may also activate β1+2AR-Gs signaling (Cernecka
et al., 2014), this observation may be explained by a direct stimu-
lating effect on adenylyl cyclase and subsequent norepinephrine
release. However, as will be discussed below, BRL37344 in the
presence of L-659,066 induced vasoconstriction in WKY, com-
patible with a stimulating effect on the Gi-coupled β3AR. The
potentiating effect of BRL37344 on release in SHR may there-
fore also result from β3AR-Gi stimulation, strengthening that
activated by α2AR (Figure 1).
The secretion of epinephrine was tonically down-regulated by
Gi in both WKY and SHR, indicated by the 6–7 times increase
in the plasma epinephrine concentration in PTX-treated rats. A
similar increase was seen in rats without tyramine-stimulated
norepinephrine release (Berg et al., 2012). Although the plasma
epinephrine concentration after pre-treatment with L-659,066
was less than that after PTX, the difference was not statisti-
cally significant, suggesting α2AR auto-inhibition of epinephrine
secretion to be an important although not the only regula-
tor of Gi in these cells. The secretion of epinephrine was not
reduced by milrinone or β1/1L/2AR blockade alone. It therefore
appeared that α2AR tonically inhibited the adrenal secretion of
epinephrine in both strains with little βAR influence. In spite of
this, β1/2AR blockade in both strains and also β1LAR antago-
nist in SHR potentiated the effect of L-659,066 on epinephrine
secretion, apparently with a greater effect of the β1- than the
β2AR in both strains. Thus, different from that observed for
norepinephrine release in WKY but similar to that in SHR,
β1- and β2AR in both strains and also β1LAR in SHR opposed
α2AR-mediated inhibition of the secretion of epinephrine. Like
tyramine-stimulated norepinephrine release in SHR but not in
WKY, the effect of L-659,066 on the secretion of epinephrine was
further enhanced when combined with milrinone or BRL37344
in both strains, most likely through the same mechanisms as
discussed above.
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FIGURE 8 | The effect of α2AR-antagonist on the
βAR-influence on the HR-response to tyramine-induced
norepinephrine release in WKY and SHR. The rats were
pre-treated with the peripherally restricted α2AR antagonist
L-659,066, alone or combined with βAR antagonist, as indicated
by symbol legends. Significant responses (* within symbol) and
differences between groups after 15min (brackets right of curves)
were located as indicated. Comparisons were made between the
control and the experimental groups, and between corresponding
L-659,066 and βAR antagonist + L-659,066 groups. Baselines
prior to tyramine are shown in Table 1. *P ≤ 0.05 after curve
evaluation (please see Materials and Methods for details).
The same receptors which presynaptically control cate-
cholamine release are also located postsynaptically and modu-
late vascular tension and heart rate. Tyramine induces a massive
release of norepinephrine without the normal physiological ter-
mination of the response by synaptic norepinephrine re-uptake
through NET. One may therefore expect the concentration of
norepinephrine within the synapse to be more than sufficient
to maximally stimulate the postsynaptic receptors in all groups
even though norepinephrine release differed. Differences in the
cardiovascular response were therefore likely to be primarily
due to drug influence on the postsynaptic receptors rather than
reflect differences in release due to drug effect on the presy-
naptic receptors. This conclusion was supported by the fact
that the tyramine-induced tachycardia was clearly hampered by
β1- and β2AR antagonists also in the presence of L-659,066
which greatly increased the level of circulating catecholamines.
The effect of tyramine does not depend on neuronal action
potentials and is therefore not directly influenced by differ-
ences in neuronal activity. Due to the anesthesia, the cardio-
vascular response to tyramine was not modified by activation
of baroreflexes, demonstrated by that the HR-response to tyra-
mine was not influenced by atropine (Berg and Jensen, 2013).
Moreover, large changes in BP induced by bradykinin or phenyle-
phrine had no effect on HR in similarly anesthetized rats of both
strains (Bjørnstad-Østensen and Berg, 1994; Berg et al., 2012).
Norepinephrine release was also not much influenced by the
ganglion blocker hexamethonium, but being a nicotine recep-
tor antagonist; it clearly reduced epinephrine secretion in both
strains (Berg, 2014a). The vasoconstrictory TPR-response to the
tyramine-induced norepinephrine release was due to α1AR acti-
vation since it was totally abolished by prazosin (Berg et al.,
2010). However, concomitant vascular α2AR-βAR-activation will
modulate this response, and this modulation differed in the
two strains. In WKY, the norepinephrine-induced vasoconstric-
tion was totally eliminated by PTX and L-659,066, showing that
α2AR-Gi-signaling was a major preserver of the α1AR-mediated
vasoconstriction in this strain. This support was due to that
α2AR-Gi-signaling opposed β1- and β2AR-mediated vasodilata-
tion, indicated by that β1- or β2AR antagonist prevented in part
the L-659,066-dependent elimination of TPR-response to tyra-
mine in WKY. Furthermore, accumulation of cAMP after pre-
treatment with milrinone clearly reduced the peak-response to
tyramine, and, in addition, potentiated the effect of L-659,066,
thus precipitating a vasodilatory response to tyramine in mil-
rinone + L-659,066-treated WKY. SR59230A did not alter the
TPR-response to tyramine in WKY (Berg, 2014b) or in L-
659,066-treated WKY, showing that β3/1LAR were not active
and did not influence this response. Thus, when α2AR-mediated
inhibition of adenylyl cyclase was prevented by L-659,066, an
increased β1+2AR-dependent vasodilatation in response to the
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released norepinephrine and/or epinephrine was allowed. When
in addition the degradation of cAMP was blocked, this effect was
further enhanced (Figure 2). Thus, α2AR-βAR-modulation of the
α1AR-mediated vasoconstriction was clearly functional in WKY.
In SHR, PTX, and L-659,066 reduced the TPR-peak-response
but not the later response to tyramine, but, different from that
in WKY, the TPR-response was not eliminated, and was not
enhanced by additional pre-treatment with β1,1L,2AR antag-
onist. The slight delay observed in the development of the
TPR-response in SHR pre-treated with SR59230A + L-659,066,
may possibly result from inhibition of β3AR-Gi-signaling.
Thus, under the present conditions, there was little interac-
tion between α2AR and βAR in the control of vascular tension
in SHR. In pathophysiological conditions, including hyperten-
sion, enhanced activation of the phospholipase C (PLC)–protein
kinase C pathway may lead to inhibition of vasodilatory voltage-
sensitive K+ channels (KV) (Ko et al., 2010) (Figure 2). The pres-
ence of such inhibition in SHR was in fact confirmed by that
antagonists against α1AR or angiotensin AT1 and ETA receptors,
which all activate PLC, enhanced the acute vasoconstrictory TPR-
response to the KV inhibitor 4-aminopyridine in SHR but not
WKY (Berg, 2003). Since cAMP-induced vasodilatation may be
mediated through a protein kinase A (PKA)-dependent open-
ing of KV (Aiello et al., 1998), the PLC-dependent inhibition
of KV in SHR was therefore likely to interfere with the α2AR-
Gi/βAR-Gs-cAMP control of vascular tension (Figure 2). A PLC-
dependent inhibition of KV in SHR may therefore explain the
absence of α2AR- and βAR-modulation of the TPR-response to
tyramine-stimulated norepinephrine release in this strain. How-
ever, when α2AR-Gi-signaling was prevented by L-659,066, and,
at the same time, cAMP-signaling was amplified by milrinone,
cAMP-mediated vasodilatation dominated the vascular tension
response also in SHR. Thus, milrinone + L-659,066 eliminated
tyramine-induced vasoconstriction in SHR. However, the effect
was still less than that in WKY where milrinone + L-659,066
precipitated a tyramine-induced vasodilatation.
When the β3AR were stimulated with the agonist BRL37344
in WKY, the inhibitory effect of L-659,066 on the TPR-response
to tyramine was reversed, with a stronger effect as cate-
cholamine release progressed. This effect of BRL37344 could not
be explained by its weak β1+2AR agonistic effect (Dolan et al.,
1994), and BRL37344 did not interact with the putative β4AR
(Malinowska and Schlicker, 1997), later identified as the β1LAR
(Granneman, 2001; Kaumann et al., 2001). Since the β3AR is
more resistant to catecholamine-induced desensitization than
β1/2AR in human tissue (Wallukat, 2002; Rouget et al., 2004),
this subtype may play a more prominent role during prolonged,
high levels of norepinephrine such as during the late part of
the tyramine-infusion period, particularly when combined with
selective agonist. This vasoconstrictory component was likely to
be mediated through β3AR-Gi signaling.
The tyramine-induced tachycardia was reduced after β1-,
β2-, and β1L(3)AR antagonist in WKY also in the presence of
L-659,066, apparently due to inhibition of postsynaptic βAR,
independent of changes in norepinephrine release. In SHR, the
tachycardia was reduced after L-659,066, halved after milrinone
+ L-659,066 and slightly increased after ICI-118551 + L-659,066.
The reason for these changes was not obvious, but may result
from receptor desensitization in the two former groups, and a
possible switch from Gs to Gi for the β2AR (Daaka et al., 1997) in
the latter group.
Conclusions
α2AR-mediated inhibition of norepinephrine release required
the presence of β2AR in WKY, but was independent of β1AR
activity. The balanced α2AR-β2AR interaction in WKY may
function to prevent excessive norepinephrine release during
physiological conditions with increased epinephrine secretion
such as hypoglycemia and exercise, since epinephrine is a
better agonist for the β2AR subtype than norepinephrine. In
SHR, α2AR inhibition of norepinephrine release was counter-
acted by β1AR and β2AR activity, with an apparently stronger
effect of the former. Although an α2AR-Gi tonic inhibi-
tion dominated the control of epinephrine secretion in both
strains, their function was counter-acted by β2AR and even
more by β1AR in both strains. The more prominent role of
β1AR in counter-acting α2AR auto inhibition of catecholamine
release in SHR may explain why β1AR blockers are use-
ful as antihypertensive medication and protective in myocar-
dial infarction and heart failure. The α1AR-mediated, vaso-
constrictory TPR-response during tyramine-stimulated nore-
pinephrine release was modulated by α2AR and β1/2AR in
WKY. The latter interaction was not functional in SHR,
most likely due to a PLC-dependent, reduced KV vasodila-
tory influence on VSMC tension, a substrate for cAMP-induced
vasodilatation.
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